Icatibant

Mechanism

A drug used to treat acute attacks of hereditary angioedema (HAE) — episodes of severe, potentially life-threatening swelling of the face, throat, abdomen, or limbs. It works by blocking the bradykinin B2 receptor — bradykinin is the molecule that causes the swelling in HAE. Given as a single subcutaneous injection, it provides relief within 30-60 minutes and patients can self-administer at home.

Effects

**Vascular/Inflammatory System (Tier 1 — FDA-approved):** Icatibant is a synthetic decapeptide that acts as a selective, competitive antagonist of the bradykinin B2 receptor. In hereditary angioedema (HAE), C1-esterase inhibitor deficiency leads to uncontrolled activation of the kallikrein-kinin system, producing excess bradykinin. Bradykinin binds B2 receptors on endothelial cells, causing: vasodilation, increased vascular permeability, edema formation, smooth muscle contraction, and pain signaling. Icatibant blocks ALL of these bradykinin-mediated effects. **HAE Attack Resolution (Tier 1):** In acute HAE attacks, icatibant produces symptom relief within 30-60 minutes of SC injection. Median time to clinically significant improvement: 2 hours. Median time to near-complete resolution: 5-8 hours. Effective for all attack locations: cutaneous (peripheral edema), abdominal (visceral edema causing severe pain), and laryngeal (potentially life-threatening airway edema). Single 30mg dose is sufficient for most attacks; can re-dose at 6-hour intervals if needed (max 3 doses/24 hours). **Cardiovascular (Tier 2):** Bradykinin B2 receptor blockade has cardiovascular implications — bradykinin is normally cardioprotective (vasodilatory, anti-thrombotic). Short-term B2 blockade with icatibant is safe, but theoretical concerns exist about repeated use affecting cardiovascular homeostasis. No clinical cardiovascular adverse events documented in HAE populations despite repeated use. **Pain/Nociception (Tier 2):** Bradykinin is one of the most potent pain-producing substances in the body. Icatibant provides significant pain relief during HAE attacks, particularly abdominal attacks which can mimic acute abdomen. The analgesic effect is secondary to blocking bradykinin's action on sensory nerve endings.

Practitioner Guide

**HAE Acute Attack Treatment:** - Dose: 30mg SC (pre-filled syringe — Firazyr) - Single injection in the abdominal area - Self-injectable — patients trained to self-administer at first sign of attack - May repeat 30mg dose at 6-hour intervals if symptoms recur or persist (maximum 3 injections/24 hours) - Effective for all attack types: peripheral (skin/extremity), abdominal, and laryngeal **When to Use:** - At first sign of an HAE attack — early treatment = faster resolution - Laryngeal attacks: administer immediately AND seek emergency care (airway compromise is life-threatening even with treatment) - Abdominal attacks: can prevent ER visits for severe abdominal pain - Patients should carry icatibant at all times (does not require refrigeration) **Clinical Pearls:** - Icatibant treats acute attacks ONLY — it is not for prophylaxis - For HAE prophylaxis: lanadelumab (Takhzyro), berotralstat (Orladeyo), or C1-INH replacement - Injection site reactions are very common (~97%) but self-limiting: erythema, swelling, burning at injection site lasting 30-60 minutes - No significant drug interactions - Safe in pregnancy (no teratogenic signal in animal studies, limited human data) - Can be used alongside C1-INH replacement therapy if needed for severe attacks **HAE Type Specificity:** - Effective in HAE Type I (85% of HAE — low C1-INH levels) and Type II (15% — dysfunctional C1-INH) - Effective in HAE with normal C1-INH (Type III / HAE-FXII) — these attacks are also bradykinin-mediated - NOT effective for histamine-mediated angioedema (allergic angioedema, ACE-inhibitor angioedema responds variably) - ACE-inhibitor angioedema: off-label icatibant use has been reported with mixed results — some case series show benefit (ACE-inhibitors increase bradykinin by blocking its degradation)

Evidence

• Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial

  William R. Lumry et al. (2011) — Ann Allergy Asthma Immunol — PMID: 22123383

  In FAST-3, icatibant significantly reduced median time to 50% symptom reduction versus placebo in acute hereditary angioedema attacks (2.0 vs 19.8 hours; P<0.001), with faster onset of symptom relief and no rescue medication needed before relief in treated subjects. Injection site reactions were common, but serious safety events were not increased.

  strong

Research Summary

**Tier 1 — FDA-approved:** - FDA approved 2011 (Firazyr) for acute HAE attacks in adults (18+), expanded to ages 2+ in 2019 - FAST-1 (n=56) and FAST-2 (n=74) pivotal phase III RCTs: icatibant vs. placebo (FAST-1) and vs. tranexamic acid (FAST-2) - FAST-3 (n=98): confirmed efficacy and safety, supported label expansion - Median time to onset of symptom relief: 2.0 hours; time to near-complete resolution: 5.0 hours - Significantly superior to tranexamic acid (p<0.001) and placebo (FAST-1 trend, FAST-3 confirmed) **Tier 2 — Established Clinical Evidence:** - Real-world evidence: Icatibant Outcome Survey (IOS) — largest real-world HAE registry, >5,000 attacks treated, confirming pivotal trial results - Self-administration feasibility: >95% of patients successfully self-inject after training - Repeat dosing safety: patients using icatibant for years (hundreds of attacks) without tachyphylaxis or cumulative toxicity - Pediatric data: safety and efficacy confirmed in children 2-17 years **Tier 3 — Emerging/Off-label:** - ACE-inhibitor angioedema: case series and small trials showing benefit (not FDA-approved for this indication) - Investigation in other bradykinin-mediated conditions: COVID-19 associated angioedema (bradykinin storm hypothesis), neuropathic pain - Oral bradykinin B2 antagonists in development as potential replacements for injectable icatibant